Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update Announced additional interim data...
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares BOSTON and LONDON, Sept. 12...
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares BOSTON and LONDON, Sept. 11, 2024 (GLOBE...
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived...
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R...
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 Company advancing pipeline of potential...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads